CONMED Corporation (CNMD) — Analysis Summary
CONMED Corporation (CNMD) has a market cap of $1.36B with year-over-year revenue growth of +5.2%. Net margin stands at 3.4%. The stock trades at a P/E ratio of 24.0.
Key Takeaways
- Revenue changed +5.2% year-over-year
- Net margin of 3.4%
- P/E ratio of 24.0
Compared to other companies in the ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS sector, CNMD posted revenue growth of +5.2% and trades at a P/E of 24.0.
CONMED Corporation (CNMD)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Debt/EBITDA at 6.6x — highly leveraged, potential refinancing risk
Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Employees
3,900
Headquarters
LARGO, FL
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$0.80
Dividend Yield
1.76%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.